Label-free MSE proteomic analysis of chronic myeloid leukemia bone marrow plasma: disclosing new insights from therapy resistance

• Published in: Proteomics (Weinheim) Vol. 12; no. 17; pp. 2618 - 2631
• Main Authors: Pizzatti, Luciana, Panis, Carolina, Lemos, Gabriela, Rocha, Moisés, Cecchini, Rubens, Souza, Gustavo H. M. F., Abdelhay, Eliana
• Format: Journal Article
• Language: English
• Published: Germany Blackwell Publishing Ltd 01.08.2012; Wiley Subscription Services, Inc
• Subjects: Adult; Antineoplastic Agents - pharmacology; Benzamides; Bone marrow; Bone Marrow - drug effects; Bone Marrow - metabolism; Bone Marrow - pathology; CML; Drug Resistance, Neoplasm; Female; Humans; Imatinib Mesylate; Label-free quantitation; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Lipid Metabolism - drug effects; Lipid peroxidation; Lipid Peroxidation - drug effects; Male; Mass Spectrometry - methods; Middle Aged; Piperazines - pharmacology; Plasma; Protein Kinase Inhibitors - pharmacology; Protein-Tyrosine Kinases - antagonists & inhibitors; ProteinLynxGlobalServer; Proteome - metabolism; Proteomics - methods; Pyrimidines - pharmacology; Stem cells; Wnt Signaling Pathway - drug effects; WNT signalling; Young Adult

Chronic myeloid leukemia (CML) is a pluripotent hematopoietic disorder that is currently considered incurable. The tyrosine kinase product of the Philadelphia chromosome, P210 BCR‐ABL, provided a pathogenetic explanation for the initiation of the CML chronic phase and is the molecular therapeutic ta...